Developer docs
API playgroundTry for free, no card

Search company profiles

Thymmune Therapeutics

Full company profile

uuid0000usx

Namestring
Thymmune Therapeutics
Legal namestring
Thymmune Therapeutics
Websiteurl
thymmune.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Thymmune Therapeutics is a preclinical-stage biotechnology company developing a machine learning-enabled thymic cell engineering platform that mass-produces induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) to restore immune function. The company's core thesis is that thymic decline underlies a broad set of conditions including primary immunodeficiencies (for example, children born without a functional thymus), transplant-related immune complications, autoimmune disorders, and immune dysfunction associated with aging. Its lead product candidate, THY-100, is advancing through preclinical studies for immune system disorders caused by thymic deficiencies, and management has signaled intent to expand the pipeline across additional immunology indications. The platform is positioned as a less invasive, off-the-shelf alternative to surgical thymus tissue transplantation, claiming scalability and reproducibility advantages that address the supply constraints of the incumbent surgical approach.

The company's scientific leadership is anchored by founder and CEO Stan Wang (MD, PhD, Stanford-trained), CSO Bing Lim (MD, PhD), and scientific advisor George Church (Harvard/MIT), with Manish Jain joining as CTO in July 2024 bringing process development and manufacturing experience from Amgen, ImmunoGen, Momenta Pharmaceuticals, Genocea, and Avenge Bio. Thymmune is based at 215 First Street, Suite 401 in Kendall Square, Cambridge, MA, near academic medical centers and major pharma R&D operations.

Thymmune is pre-revenue with no products approved or in clinical trials. Its business model is biopharmaceutical development and commercialization, targeting eventual one-time therapeutic product sales post-FDA approval and distribution through healthcare providers, academic medical centers, and transplant centers. To date the company has raised approximately $44 million in total funding, comprising a $7 million seed round led by Pillar VC (March 2023) with participation from NYBC Ventures and individual investors, and up to $37 million in non-dilutive grant funding from ARPA-H for the Thymus Rejuvenation project (September 2023), the first industry award under the ARPA-H Open Broad Agency Announcement. Earlier validation includes five 2021 Golden Tickets from Astellas, Boehringer Ingelheim, LG Chem Life Sciences, Novo Nordisk, and Pfizer, alongside NIH/NIAID SBIR and Wellcome Leap HOPE program funding.

Short descriptiontext

Thymmune Therapeutics is a preclinical-stage biotechnology company developing a machine learning-enabled platform to mass-produce iPSC-derived thymic epithelial cells (iPS-TECs) aimed at restoring immune function in patients with thymic deficiencies, transplant-related immune disorders, autoimmune diseases, and aging-related immune decline, with lead candidate THY-100 advancing through preclinical studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy platform, thymic cell engineering, iPSC-derived therapeutics, immune system restoration, regenerative biotechnology
Industry1 code
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Regenerative Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue company developing a pipeline of thymic cell therapies targeting immunodeficiencies, transplant-related, and autoimmune disorders. Revenue will be generated through eventual therapeutic product sales following FDA approval.

thymmune.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Thymmune Therapeutics is developing a machine learning-enabled thymic cell engineering platform that produces induced pluripotent stem cell (iPSC)-derived thymic epithelial cells (iPS-TECs) at scale for off-the-shelf cell therapies. Its lead product candidate, THY-100, is in preclinical development for immune system disorders caused by thymic deficiencies. The company is building a pipeline targeting immunodeficiencies, transplant-related immune complications, autoimmune diseases, and aging-related immune decline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale
+1 more record
Product overview1 text field

Thymmune Therapeutics is developing a machine learning-enabled thymic cell engineering platform for restoring immune function in aging and disease. The core platform enables mass production of iPSC-derived thymic cells (iPS-TECs) to generate off-the-shelf cells at scale. The company's lead product candidate is THY-100, which is advancing through preclinical studies for immune disorders caused by thymic deficiencies. The pipeline includes therapies targeting immunodeficiencies, transplant-related, and autoimmune diseases. The company also received $37M in ARPA-H funding for the Thymus Rejuvenation project focused on developing human iPS-TEC therapies.

Product and service2 records
1Machine Learning-Enabled Thymic Cell Engineering Platform
CategoryCell Therapy Platform / Regenerative Medicine
Description

A proprietary platform that enables mass production of iPSC-derived thymic epithelial cells (iPS-TECs) to restore immune function through a less invasive, off-the-shelf approach that can be replicated at high quality at scale. The platform combines machine learning with decades of thymus gland research to develop novel therapies for immune system disorders.

2THY-100
CategoryCell Therapy Product Candidate
Description

Lead product candidate for immune system disorders caused by thymic deficiencies, such as children born without a thymus, which result in a lack of functional T cells. THY-100 is being advanced into preclinical studies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Enzyvant commercializes RETHYMIC, the only FDA-approved thymus tissue product, a surgical approach for congenital athymia. It is the closest direct competitor to Thymmune's off-the-shelf iPSC-TEC approach, targeting the same patient population with a more scalable, less invasive cell therapy modality.

TypeEmerging player
Description

Sonoma develops regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. It overlaps with Thymmune on immune-mediated disease targeting and uses cell engineering approaches to modulate immune function, though via Tregs rather than thymic epithelial cells.

TypeEmerging player
Description

Cue Biopharma develops Immuno-STAT biologics that selectively modulate T cells for cancer and autoimmune disease. It is comparable to Thymmune in targeting immune system modulation through engineered biologics, though Cue uses protein-based rather than cell-based platforms.

TypeDirect peer
Description

Century develops iPSC-derived allogeneic cell therapies (NK and T cells) for cancer and autoimmune disease. It shares Thymmune's iPSC-based manufacturing approach and pipeline focus on immune-mediated diseases, making it a directly comparable engineered cell therapy peer.

TypeDirect peer
Description

Fate is a pioneer in iPSC-derived off-the-shelf NK and T cell therapies for cancer and autoimmune indications. Its iPSC platform and off-the-shelf cell therapy model closely mirror Thymmune's approach, though Fate's cell types and indications differ.

TypeBroad incumbent
Description

Sana develops engineered cells and gene therapy approaches for a broad range of diseases, including immune-mediated conditions. As a well-capitalized public cell and gene therapy company, it represents a broader incumbent in the engineered cell therapy space adjacent to Thymmune.

TypeBroad incumbent
Description

Lyell develops T cell therapies for solid tumors with a focus on cell state and persistence. It shares Thymmune's cell therapy engineering focus and immune system orientation, though Lyell focuses on oncology rather than immune restoration.

TypeEmerging player
Description

Adicet develops off-the-shelf gamma delta T cell therapies for autoimmune disease and cancer. It is comparable to Thymmune as an allogeneic cell therapy developer targeting immune-mediated diseases, though with a different immune cell type.

TypeOthers
Description

Ginkgo Bioworks operates a cell engineering platform leveraging synthetic biology and machine learning for organism programming. It is comparable to Thymmune as a platform company combining ML with cell engineering, though Ginkgo operates as a CRO/tech platform rather than developing its own therapeutic products.

TypeOthers
Description

Insitro combines machine learning with high-throughput biology for drug discovery across multiple therapeutic areas. It is comparable to Thymmune in its use of ML-driven approaches to biological engineering and therapeutic development, though Insitro focuses on small molecule and biologics discovery rather than cell therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Thymmune Therapeutics

Cell Therapy / Regenerative Medicinethymmune.com

Thymmune Therapeutics is a preclinical-stage biotechnology company developing a machine learning-enabled platform to mass-produce iPSC-derived thymic epithelial cells (iPS-TECs) aimed at restoring immune function in patients with thymic deficiencies, transplant-related immune disorders, autoimmune diseases, and aging-related immune decline, with lead candidate THY-100 advancing through preclinical studies.

What Thymmune Therapeutics does

Thymmune Therapeutics is a preclinical-stage biotechnology company developing a machine learning-enabled thymic cell engineering platform that mass-produces induced pluripotent stem cell-derived thymic epithelial cells (iPS-TECs) to restore immune function. The company's core thesis is that thymic decline underlies a broad set of conditions including primary immunodeficiencies (for example, children born without a functional thymus), transplant-related immune complications, autoimmune disorders, and immune dysfunction associated with aging. Its lead product candidate, THY-100, is advancing through preclinical studies for immune system disorders caused by thymic deficiencies, and management has signaled intent to expand the pipeline across additional immunology indications. The platform is positioned as a less invasive, off-the-shelf alternative to surgical thymus tissue transplantation, claiming scalability and reproducibility advantages that address the supply constraints of the incumbent surgical approach.

The company's scientific leadership is anchored by founder and CEO Stan Wang (MD, PhD, Stanford-trained), CSO Bing Lim (MD, PhD), and scientific advisor George Church (Harvard/MIT), with Manish Jain joining as CTO in July 2024 bringing process development and manufacturing experience from Amgen, ImmunoGen, Momenta Pharmaceuticals, Genocea, and Avenge Bio. Thymmune is based at 215 First Street, Suite 401 in Kendall Square, Cambridge, MA, near academic medical centers and major pharma R&D operations.

Thymmune is pre-revenue with no products approved or in clinical trials. Its business model is biopharmaceutical development and commercialization, targeting eventual one-time therapeutic product sales post-FDA approval and distribution through healthcare providers, academic medical centers, and transplant centers. To date the company has raised approximately $44 million in total funding, comprising a $7 million seed round led by Pillar VC (March 2023) with participation from NYBC Ventures and individual investors, and up to $37 million in non-dilutive grant funding from ARPA-H for the Thymus Rejuvenation project (September 2023), the first industry award under the ARPA-H Open Broad Agency Announcement. Earlier validation includes five 2021 Golden Tickets from Astellas, Boehringer Ingelheim, LG Chem Life Sciences, Novo Nordisk, and Pfizer, alongside NIH/NIAID SBIR and Wellcome Leap HOPE program funding.

Thymmune Therapeutics firmographics

Firmographics
Name
Thymmune Therapeutics
Legal name
Thymmune Therapeutics
Website
https://thymmune.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Thymmune Therapeutics is a preclinical-stage biotechnology company developing a machine learning-enabled platform to mass-produce iPSC-derived thymic epithelial cells (iPS-TECs) aimed at restoring immune function in patients with thymic deficiencies, transplant-related immune disorders, autoimmune diseases, and aging-related immune decline, with lead candidate THY-100 advancing through preclinical studies.
Ownership category
akta.pro rank

Thymmune Therapeutics industry classification

Industry
Product category
Cell Therapy / Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy platform
  • Thymic cell engineering
  • IPSC-derived therapeutics
  • Immune system restoration
  • Regenerative biotechnology

Where Thymmune Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Thymmune Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development and Commercialization: Pre-revenue company developing a pipeline of thymic cell therapies targeting immunodeficiencies, transplant-related, and autoimmune disorders. Revenue will be generated through eventual therapeutic product sales following FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Thymmune Therapeutics product offering

Product offering

Core offering

Thymmune Therapeutics is developing a machine learning-enabled thymic cell engineering platform that produces induced pluripotent stem cell (iPSC)-derived thymic epithelial cells (iPS-TECs) at scale for off-the-shelf cell therapies. Its lead product candidate, THY-100, is in preclinical development for immune system disorders caused by thymic deficiencies. The company is building a pipeline targeting immunodeficiencies, transplant-related immune complications, autoimmune diseases, and aging-related immune decline.

Product overview

Thymmune Therapeutics is developing a machine learning-enabled thymic cell engineering platform for restoring immune function in aging and disease. The core platform enables mass production of iPSC-derived thymic cells (iPS-TECs) to generate off-the-shelf cells at scale. The company's lead product candidate is THY-100, which is advancing through preclinical studies for immune disorders caused by thymic deficiencies. The pipeline includes therapies targeting immunodeficiencies, transplant-related, and autoimmune diseases. The company also received $37M in ARPA-H funding for the Thymus Rejuvenation project focused on developing human iPS-TEC therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Machine Learning-Enabled Thymic Cell Engineering Platform A proprietary platform that enables mass production of iPSC-derived thymic epithelial cells (iPS-TECs) to restore immune function through a less invasive, off-the-shelf approach that can be replicated at high quality at scale. The platform combines machine learning with decades of thymus gland research to develop novel therapies for immune system disorders.
  • THY-100 Lead product candidate for immune system disorders caused by thymic deficiencies, such as children born without a thymus, which result in a lack of functional T cells. THY-100 is being advanced into preclinical studies.

Quantifiable outcome

  • iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale
  • +1 more outcomes

Companies that use Thymmune Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Thymmune Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Thymmune Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Thymmune Therapeutics competitors and assessment

Company assessment

Direct peers

  • Enzyvant Therapeutics: Enzyvant commercializes RETHYMIC, the only FDA-approved thymus tissue product, a surgical approach for congenital athymia. It is the closest direct competitor to Thymmune's off-the-shelf iPSC-TEC approach, targeting the same patient population with a more scalable, less invasive cell therapy modality.
  • Century Therapeutics: Century develops iPSC-derived allogeneic cell therapies (NK and T cells) for cancer and autoimmune disease. It shares Thymmune's iPSC-based manufacturing approach and pipeline focus on immune-mediated diseases, making it a directly comparable engineered cell therapy peer.
  • Fate Therapeutics: Fate is a pioneer in iPSC-derived off-the-shelf NK and T cell therapies for cancer and autoimmune indications. Its iPSC platform and off-the-shelf cell therapy model closely mirror Thymmune's approach, though Fate's cell types and indications differ.

Emerging players

  • Sonoma Biotherapeutics: Sonoma develops regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. It overlaps with Thymmune on immune-mediated disease targeting and uses cell engineering approaches to modulate immune function, though via Tregs rather than thymic epithelial cells.
  • Cue Biopharma: Cue Biopharma develops Immuno-STAT biologics that selectively modulate T cells for cancer and autoimmune disease. It is comparable to Thymmune in targeting immune system modulation through engineered biologics, though Cue uses protein-based rather than cell-based platforms.
  • Adicet Bio: Adicet develops off-the-shelf gamma delta T cell therapies for autoimmune disease and cancer. It is comparable to Thymmune as an allogeneic cell therapy developer targeting immune-mediated diseases, though with a different immune cell type.

Broad incumbents

  • Sana Biotechnology: Sana develops engineered cells and gene therapy approaches for a broad range of diseases, including immune-mediated conditions. As a well-capitalized public cell and gene therapy company, it represents a broader incumbent in the engineered cell therapy space adjacent to Thymmune.
  • Lyell Immunopharma: Lyell develops T cell therapies for solid tumors with a focus on cell state and persistence. It shares Thymmune's cell therapy engineering focus and immune system orientation, though Lyell focuses on oncology rather than immune restoration.

Others

  • Ginkgo Bioworks: Ginkgo Bioworks operates a cell engineering platform leveraging synthetic biology and machine learning for organism programming. It is comparable to Thymmune as a platform company combining ML with cell engineering, though Ginkgo operates as a CRO/tech platform rather than developing its own therapeutic products.
  • Insitro: Insitro combines machine learning with high-throughput biology for drug discovery across multiple therapeutic areas. It is comparable to Thymmune in its use of ML-driven approaches to biological engineering and therapeutic development, though Insitro focuses on small molecule and biologics discovery rather than cell therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Thymmune Therapeutics social profiles

Digital presence

Thymmune Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Thymmune Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Thymmune Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Thymmune Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thymmune Therapeutics

What does Thymmune Therapeutics do?

Thymmune Therapeutics is developing a machine learning-enabled thymic cell engineering platform that produces induced pluripotent stem cell (iPSC)-derived thymic epithelial cells (iPS-TECs) at scale for off-the-shelf cell therapies. Its lead product candidate, THY-100, is in preclinical development for immune system disorders caused by thymic deficiencies. The company is building a pipeline targeting immunodeficiencies, transplant-related immune complications, autoimmune diseases, and aging-related immune decline.

Is Thymmune Therapeutics a public or private company?

Thymmune Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Thymmune Therapeutics founded?

Thymmune Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Thymmune Therapeutics based?

Thymmune Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Thymmune Therapeutics make money?

One revenue line is on record: biopharmaceutical Development and Commercialization.

Who are Thymmune Therapeutics's main competitors?

Direct peers on record are Enzyvant Therapeutics, Century Therapeutics and Fate Therapeutics. Emerging players are Sonoma Biotherapeutics, Cue Biopharma and Adicet Bio. Broad incumbents are Sana Biotechnology and Lyell Immunopharma. Others are Ginkgo Bioworks and Insitro.

Does Thymmune Therapeutics have an API?

No public API is recorded for Thymmune Therapeutics.

What industry is Thymmune Therapeutics in?

Thymmune Therapeutics's product category is Cell Therapy / Regenerative Medicine. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comUnited Therapeutics earnings on deck after first-quarter miss By Investing.comUnited Therapeutics Corporation is scheduled to report second-quarter earnings on August 5, 2026, following a first-quarter revenue miss of $781.5 million that marked a 1.6% year-over-year decline and sent shares tumbling in May. Analysts project Q2 earnings of $7.09 per share on revenue of $807.05 million, representing sequential improvement though revenue growth is expected to remain muted at just 1.1% year-over-year. The company recently expanded its pipeline through the acquisition of Thymmune Therapeutics and FDA approval for its LungFX device, as it seeks to diversify beyond its core pulmonary arterial hypertension franchise.AInvestUTTHR Leads Daily Turnover Rankings With $290M Surge Amid Strategic Thymmune DealUnited Therapeutics Corporation (NASDAQ: UTHR) saw $290 million in trading volume on July 7, 2026, a 60.55% surge that led daily market rankings, with the stock rising a modest 3.01%. The trading activity was driven by United Therapeutics' agreement to acquire Thymmune Therapeutics for $140 million upfront (plus up to $160 million in milestone payments), bringing preclinical thymic cell therapy THY-100 into its portfolio. Despite recent earnings misses ($5.82 EPS vs $7.00 estimate, $781.5M revenue vs $797.4M estimate), strong institutional buying (94% ownership, with Wellington Management raising its stake 74.5%) and a "Moderate Buy" analyst consensus with a $619.42 average price target suggest continued confidence in the company's growth strategy.Pulse 2.0Why United Therapeutics Acquired Thymmune Therapeutics For Up To $300 MillionUnited Therapeutics has acquired Thymmune Therapeutics, a preclinical-stage biotechnology company developing scalable regenerative thymic cell therapies, for $140 million in cash plus up to $160 million in potential earn-out payments tied to clinical and regulatory milestones through 2031. Thymmune's lead candidate THY-100 is in preclinical development for congenital athymia, an ultra-rare life-threatening condition in which infants are born without a functional thymus. The acquisition supports United Therapeutics' mission to expand the supply of transplantable organs and complements its UThymoKidney clinical development program and immunomodulatory therapeutics work.The Pharma LetterUnited Thera acquires Thymmune for $140 millionUnited Therapeutics (Nasdaq: UTHR) has acquired Thymmune Therapeutics, a privately held pre-clinical stage biotech company, for $140 million. Thymmune specializes in regenerative thymic cell therapies derived from human-induced pluripotent stem cells, targeting post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The acquired technology enables in-body maturation into cell types that restore healthy T-cell function.BenzingaUnited Therapeutics Expands Immune Therapy Pipeline With Thymmune - United Therapeutics (NASDAQ:UTHR)United Therapeutics Corp. has acquired privately held Thymmune Therapeutics for $140 million in cash upfront, with additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through the end of 2031. Thymmune is a preclinical-stage biotechnology company developing regenerative thymic cell therapies, with its lead candidate THY-100 targeting congenital athymia, an ultra-rare condition in which infants are born without a functioning thymus. The deal expands United Therapeutics' immune therapy pipeline by adding a proprietary platform that uses human-induced pluripotent stem cells to restore T-cell function.citybizUnited Therapeutics Expands Regenerative Medicine Pipeline with $140M Thymmune AcquisitionUnited Therapeutics has acquired Thymmune Therapeutics, a preclinical biotech company developing regenerative thymic cell therapies, in a deal worth $140 million upfront with potential additional milestone payments up to $160 million. The acquisition expands United Therapeutics' regenerative medicine portfolio, adding Thymmune's lead candidate THY-100 for congenital athymia and its iPSC-based platform for restoring T-cell function in organ transplant tolerance and autoimmune diseases. United Therapeutics reported Q1 2026 revenue of approximately $794 million, up from $677 million year-over-year, and holds more than $3 billion in cash and investments.BenzingaUnited Therapeutics Acquires Thymmune Therapeutics For $140M In Cash - United Therapeutics (NASDAQ:UTHR)United Therapeutics Corporation has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company, for $140 million in cash. The deal includes potential earn-out payments of up to $160 million tied to the achievement of clinical and regulatory milestones by the end of 2031. Thymmune develops scalable regenerative thymic cell therapies targeting post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.Business Wire BlogUnited Therapeutics Corporation Acquires Thymmune TherapeuticsUnited Therapeutics Corporation has acquired Thymmune Therapeutics, a preclinical-stage biotechnology company developing scalable regenerative thymic cell therapies, for $140 million in cash with potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through the end of 2031. Thymmune's lead candidate THY-100 is in preclinical development for congenital athymia, an ultra-rare condition in which infants are born without a functional thymus, and uses a proprietary process to convert human-induced pluripotent stem cells into thymic cells that can restore healthy T-cell function. United Therapeutics stated that the acquisition complements its mission to expand transplantable organ supply and builds on its UThymoKidney clinical development program and immunomodulatory therapeutics capabilities.Stock TitanUnited Therapeutics acquires Thymmune for $140MUnited Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $140 million in cash with additional earn-out payments of up to $160 million tied to clinical and regulatory milestones by the end of 2031. Thymmune is a preclinical-stage biotechnology company developing regenerative thymic cell therapies targeting post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases, with its lead candidate THY-100 in preclinical development for congenital athymia. United Therapeutics stated the acquisition complements its mission to expand the supply of transplantable organs, building on its UThymoKidney clinical development program.FinancialContent Business PageUnited Therapeutics Corporation Acquires Thymmune TherapeuticsUnited Therapeutics Corporation has acquired Thymmune Therapeutics, Inc., a preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies, for $140 million in cash with potential earn-out payments of up to $160 million based on clinical and regulatory milestones by the end of 2031. Thymmune's lead candidate THY-100 is in preclinical development for congenital athymia, an ultra-rare life-threatening condition in which infants are born without a functional thymus, and its platform technology has potential applications for post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The acquisition complements United Therapeutics' mission to expand the supply of transplantable organs and strengthens its immunomodulatory therapeutics pipeline.